Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARA NASDAQ:EGRX NYSE:KDMN NASDAQ:KURA NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsEGRXEagle Pharmaceuticals$1.00-22.5%$2.83$0.11▼$3.87$12.99M0.836,502 shs5,252 shsKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsKURAKura Oncology$9.58-4.1%$8.52$5.41▼$19.73$867.10M0.321.84 million shs1.37 million shsSNDXSyndax Pharmaceuticals$15.20-2.4%$15.63$8.58▼$22.50$1.34B0.682.40 million shs2.16 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+67.23%EGRXEagle Pharmaceuticals-14.00%-14.00%-61.72%-65.04%+43.33%KDMNKadmon0.00%0.00%0.00%0.00%0.00%KURAKura Oncology+1.52%+0.60%+21.09%+49.78%-44.50%SNDXSyndax Pharmaceuticals+8.88%+2.43%+5.35%+51.02%-21.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsEGRXEagle Pharmaceuticals$1.00-22.5%$2.83$0.11▼$3.87$12.99M0.836,502 shs5,252 shsKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsKURAKura Oncology$9.58-4.1%$8.52$5.41▼$19.73$867.10M0.321.84 million shs1.37 million shsSNDXSyndax Pharmaceuticals$15.20-2.4%$15.63$8.58▼$22.50$1.34B0.682.40 million shs2.16 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+67.23%EGRXEagle Pharmaceuticals-14.00%-14.00%-61.72%-65.04%+43.33%KDMNKadmon0.00%0.00%0.00%0.00%0.00%KURAKura Oncology+1.52%+0.60%+21.09%+49.78%-44.50%SNDXSyndax Pharmaceuticals+8.88%+2.43%+5.35%+51.02%-21.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/AKDMNKadmon 0.00N/AN/AN/AKURAKura Oncology 2.63Moderate Buy$24.67157.48% UpsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$38.00150.00% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, KURA, CARA, EGRX, and KDMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.0010/20/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$24.0010/20/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.0010/16/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.0010/15/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/8/2025KURAKura OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025KURAKura OncologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell9/30/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.009/27/2025KURAKura OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00EGRXEagle Pharmaceuticals$257.55M0.05$2.50 per share0.40N/A∞KDMNKadmonN/AN/AN/AN/AN/AN/AKURAKura Oncology$53.88M15.43N/AN/A$5.32 per share1.80SNDXSyndax Pharmaceuticals$77.93M16.80N/AN/A$3.38 per share4.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AKDMNKadmonN/AN/A0.00∞N/AN/AN/AN/AN/AKURAKura Oncology-$173.98M-$2.26N/AN/AN/AN/A-52.32%-29.59%11/6/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)Latest SNDX, KURA, CARA, EGRX, and KDMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025KURAKura Oncology-$0.57N/AN/AN/A$17.48 millionN/A11/4/2025Q3 2025SNDXSyndax Pharmaceuticals-$0.73N/AN/AN/A$49.08 millionN/A8/7/2025Q2 2025KURAKura Oncology$0.15-$0.75-$0.90-$0.75$64.95 million$15.29 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71EGRXEagle PharmaceuticalsN/AN/AN/AKDMNKadmonN/AN/AN/AKURAKura Oncology0.026.166.16SNDXSyndax Pharmaceuticals2.064.714.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%EGRXEagle Pharmaceuticals85.36%KDMNKadmonN/AKURAKura OncologyN/ASNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%EGRXEagle Pharmaceuticals28.90%KDMNKadmonN/AKURAKura Oncology6.40%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataKDMNKadmonN/A178.52 millionN/AOptionableKURAKura Oncology13086.80 million81.24 millionOptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableSNDX, KURA, CARA, EGRX, and KDMN HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals (NASDAQ:SNDX) Trading 9.8% Higher - Time to Buy?October 20 at 6:40 PM | marketbeat.comBrokers Offer Predictions for SNDX Q3 EarningsOctober 20 at 2:03 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Earns Buy Rating from Analysts at HC WainwrightOctober 19 at 2:05 AM | americanbankingnews.comAberdeen Group plc Has $2.84 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDXOctober 18 at 3:34 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Illumina (ILMN)October 17, 2025 | theglobeandmail.comSyndax Pharmaceuticals (NASDAQ:SNDX) Upgraded at HC WainwrightOctober 17, 2025 | marketbeat.comWhere Syndax Pharmaceuticals Stands With AnalystsOctober 16, 2025 | benzinga.comSyndax Pharmaceuticals' (SNDX) Buy Rating Reaffirmed at HC WainwrightOctober 16, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.9% - Here's What HappenedOctober 13, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given Sell (E+) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comResearch Analysts Offer Predictions for SNDX FY2027 EarningsOctober 6, 2025 | marketbeat.comSyndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA DecisionOctober 4, 2025 | msn.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 29, 2025 | marketbeat.comSyndax announces updated NCCN Guidelines for AMLSeptember 19, 2025 | msn.comSyndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute ...September 19, 2025 | finance.yahoo.comSyndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaSeptember 19, 2025 | globenewswire.comSyndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRCSeptember 10, 2025 | seekingalpha.comSyndax resumed with Buy at Stifel on newly launched drugsSeptember 10, 2025 | msn.comStocks To Watch: Syndax Pharmaceuticals Sees Relative Strength Rating Jump To 84September 8, 2025 | msn.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, KURA, CARA, EGRX, and KDMN Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Eagle Pharmaceuticals NASDAQ:EGRX$1.00 -0.29 (-22.48%) As of 03:27 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Kadmon NYSE:KDMNKadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.Kura Oncology NASDAQ:KURA$9.58 -0.41 (-4.10%) Closing price 04:00 PM EasternExtended Trading$9.70 +0.12 (+1.20%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Syndax Pharmaceuticals NASDAQ:SNDX$15.20 -0.37 (-2.38%) Closing price 04:00 PM EasternExtended Trading$15.39 +0.19 (+1.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
